EU Rejects Illumina Acquisition Of Grail
Executive Summary
The European Union’s antitrust commission blocked the re-acquisition of Grail by Illumina days after an FTC administrative law judge ruled in favor of the merger in the US.
You may also be interested in...
News We’re Watching: Illumina Looks At Grail Options, New AdvaMed Digital Health Division, Evolut FX Gets CE Mark
This week, Illumina responded to the European Commission’s order for it to divest Grail; StrokeDX won a global innovation competition; and the US Food and Drug Administration approved expanded labeling for Boston Scientific’s WaveWriter Alpha to include painful diabetic peripheral neuropathy.
Minute Insight: The Illumina-Grail Dream Is Over... In Europe
More than a year after it first rejected the merger, the European Commission has flexed its regulatory might and has ordered the two companies to separate.
BioBytes: Against A Turbulent Corporate Backdrop, Illumina Touts New AI Gene Analysis Tool
Welcome to In Vivo’s new AI-focused blog, BioBytes, providing news and insight on the growing role of artificial intelligence in biopharma. In this post, Illumina’s new large language model-based gene analysis tool could help drive uptake of its products.